Skip to main content

Peripheral Arterial Disease (PAD)

2
Pipeline Programs
5
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Design Pharmaceuticals
2 programs
2
REX-001Phase 31 trial
REX-001Phase 31 trial
Active Trials
NCT03111238Terminated3Est. Mar 2021
NCT03174522Terminated49Est. Feb 2023
Design Therapeutics
2 programs
REX-001PHASE_3
REX-001PHASE_3
Medtronic
MedtronicNJ - Phillipsburg
1 program
Drug-Coated BalloonN/A1 trial
Active Trials
NCT01175850Completed331Est. Apr 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Design PharmaceuticalsREX-001
Design PharmaceuticalsREX-001
MedtronicDrug-Coated Balloon

Clinical Trials (3)

Total enrollment: 383 patients across 3 trials

NCT03174522Design PharmaceuticalsREX-001

The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM

Start: Apr 2017Est. completion: Feb 202349 patients
Phase 3Terminated
NCT03111238Design PharmaceuticalsREX-001

The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM

Start: Apr 2017Est. completion: Mar 20213 patients
Phase 3Terminated
NCT01175850MedtronicDrug-Coated Balloon

Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease

Start: Sep 2010Est. completion: Apr 2017331 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.